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Abstract: The insulin-like growth factor-2 (Igf2)-H19 locus encodes important paternally imprinted genes that
govern normal embryonic development. While Igf-2 encodes IGF2, which is an autocrine/paracrine mitogen,
transcription of H19 gives rise to non-coding mRNA that is a precursor of several microRNAs (miRNAs) that
negatively affect cell proliferation. The proper imprinting of a differentially methylated region (DMR) within
this locus, with methylation of the paternal chromosome and a lack of methylation on the maternal chromo-
some, regulates expression of both of these genes so that Igf2 is transcribed only from the paternal chromosome
and H19 only from the maternal chromosome. There is growing evidence that this ‘Yin-Yang’ locus regulates
embryonic development. Furthermore, recent evidence indicates that erasure of imprinting (hypomethylation)
of the Igf2-H19 locus on both chromosomes, which leads to downregulation of Igf2 and upregulation of H19
expression, plays an important role in regulating quiescence of pluripotent stem cells in adult organisms, and
may be involved in the regulation of lifespan. In contrast, hypermethylation of this locus on both chromosomes
(loss of imprinting) results in Igf2 overexpression and is observed in several malignancies. In this review, we will
discuss the biological consequences of changes in Igf2-H19 expression. (Folia Histochemica et Cytobiologica 2012,
Vol. 50, No. 2, 171–179)
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Introduction
Mammalian development requires proper gene dos-
age, which is enabled by the imprinting of genes so
that a single parental allele is expressed. In other
words, genomic imprinting is an epigenetic program
that ensures the parent-of-origin-specific monoallel-
ic transcription of imprinted genes and results in in-
tracellular expression of imprinted genes from only
one of the two paternal chromosomes, derived either
from the mother or the father [1–5].
Overall, there are ~100 paternally imprinted genes
in the mammalian genome (expressed from the ma-
ternal or paternal chromosome only) that play an
important role in embryonal development. Imprint-
ed genes play a crucial role in embryogenesis, fetal
growth, behavioral development, the totipotential
state of the zygote, and pluripotency of developmen-
tally early stem cells [4]. On the other hand, erasure
of genomic imprints is one of the mechanisms that
prevent some of the pluripotent stem cells (e.g. pri-
mordial germ cells [PGCs] and very small embryon-
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ic-like stem cells [VSELs]) from uncontrolled prolif-
eration and teratoma formation [6–13].
The expression of imprinted genes is regulated by
the imposition of epigenetic marks by DNA methyla-
tion within differentially methylated regions (DMRs),
which are CpG-rich cis-elements within their loci [1–4].
These epigenetic marks imposed on DMRs in the
female germline act on the promoters of imprinted
genes, which results in the heritable repression of the
maternal chromosomes. In contrast, the imposition
of epigenetic marks by methylation of the chromo-
somes in the male germline does not occur at the pro-
moters, but rather within the intergenic regions (i.e.
between the Igf2 and H19 genes). Imprinted genes,
in general, are highly expressed during embryogene-
sis, and many of them are subsequently downregulat-
ed after birth. Most imprinted genes are methylated
on maternally derived chromosomes, and only four:
Igf2-H19, RasGrf1, Dlk1/Dio3, and Zdbf2, are methy-
lated on paternally derived chromosomes [1–4]. In
this review, we will focus on the biological consequenc-
es of imprinting within the DMR for Igf2-H19.
The Igf2-H19 tandem gene is paternally imprint-
ed in humans as well as in mice and, as mentioned
above, the regulatory DMR for this gene is methylat-
ed on the paternal, and erased on the maternal, chro-
mosome [1–4]. Figure 1 shows a schematically sim-
plified structure for this locus. The filled lollypops at
the DMR regulatory region of the paternal chromo-
some depict methylation, and open lollypops on the
maternal chromosome indicate lack of methylation.
If the DMR is methylated, it cannot bind the regula-
tory DNA-binding zinc finger insulator protein,
CTCF, which establishes a functional boundary be-
tween the Igf2 and H19 coding regions. The binding
of CTCF has immediate consequences for the expres-
sion of these loci. Since the expression of both Igf2
and H19 is regulated from a 3’ distal enhancer (shown
as a green box), the presence of CTCF bound to the
DMR at the maternal locus prevents transcription of
Igf2, and in this situation, only H19 is transcribed to
RNA. In contrast, the presence of a methylated DMR
on the paternal chromosome prevents binding of
CTCF, and in this situation, the 3’ distal enhancer
promotes transcription of mRNA from the Igf2 lo-
cus. This ensures a proper balance in the expression
of both genes (Figure 2, upper panel).
As discussed in this review, the methylation of
DMRs within the Igf2-H19 locus is erased in pluripo-
tent stem cells, such as PGCs [6–11] and VSELs [12,
13] (Figure 2, middle panel). This epigenetic modifi-
cation of Igf2-H19 is one of the mechanisms respon-
sible for keeping these cells quiescent (low expres-
sion of Igf2 and overexpression of H19) and prevents
them from uncontrolled proliferation and teratoma
formation. In contrast, hypermethylation of DMRs
within Igf2-H19 on both maternally and paternally
derived chromosomes, which is called ‘loss of imprint-
ing’, is observed in several malignancies and results
in high expression of Igf2 (Figure 2, lower panel). Loss
of imprinting at this locus, as will be discussed later,
could also result from perturbation of other mecha-
nisms that regulate the proper Igf2:H19 expression
ratio in these cells (e.g.downregulation of CTCF ex-
pression) [14].
In this review, we will discuss the three possibili-
ties (normal somatic imprinting, erasure of imprint-
ing, and loss of imprinting) as epigenetic changes in
methylation of DMRs for the Igf2-H19 ‘master locus’
that affect several biological processes, such as prop-
er embryogenesis, proliferation of pluripotent stem
cells, senescence, and tumorogenesis.
Biological role of proper somatic
imprinting of the Igf2-H19 tandem gene
The tandem Igf2-H19 locus is located on chromosome
11p15 in humans and chromosome 7 in mice. While
the Igf2 locus encodes insulin-like growth factor-2
(IGF2), which is a growth-promoting peptide hor-
mone highly expressed during embryogenesis, the H19
locus encodes a non-coding RNA (ncRNA) that gives
rise to several microRNAs (miRNAs) that have op-
posite effects on cell proliferation [15]. The dual Yin-
Yang function of this master locus is relevant to sev-
eral biological functions, including normal fetal de-
velopment, and the properly balanced expression of
Igf2 and H19 is crucial for proper embryogenesis (Fig-
ure 2 upper panel). Imprinting at the Igf2-H19 locus
is one of the major factors preventing parthenoge-
netic development in mammals, and the biological
importance of this locus is demonstrated by the addi-
tional steps necessary for the creation of viable bima-
ternal mice derived from two female sets of chromo-
somes [1–4]. These mice are created by combining
two haploid nuclei, one from non-growing and the
other from fully growing oocytes, into a diploid ‘bi-
maternal zygote’. Since female chromosomes have
unmethylated DMRs for Igf2-H19 (Figure 1), the cru-
cial step is appropriate genetic modulation of the
proper expression of Igf2 from one of the maternally
derived sets of chromosomes [6–13].
The role of imprinted genes in development, in-
cluding the master tandem gene Igf2-H19, has been
explained by the parent–offspring conflict hypothe-
sis. While during pregnancy, the father, through prop-
er expression of paternally imprinted genes (i.e. by
expression of Igf2 and suppression of H19), contrib-
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Figure 1. Regulation of expression of the Igf2-H19 tandem gene. Left panel — Igf2 and H19 coding regions are separated
by a differentially methylated region (DMR) that is methylated (as shown by filled lollypops) on the paternal chromoso-
me and unmethylated (open lollypops) on the maternal chromosome. Expression of both genes is regulated by a 3’ distal
enhancer, depicted in green. Right panel — methylation of the DMR on the paternal chromosome prevents binding of
CTCF insulator protein and allows activation of the Igf2 promoter by the distal enhancer and transcription of Igf2 mRNA
from the paternal chromosome (red arrow). In contrast, since the DMR is unmethylated on the maternal chromosome,
it binds CTCF, and this prevents activation of the Igf2 promoter by the distal enhancer. As a result, only H19 mRNA is











Figure 2. Changes in methylation state of DMRs and their impact on Igf2 and H19 expression. Upper panel –— normal
somatic imprint observed in all somatic cells, which results, as described in Figure 1, in properly balanced expression of
Igf2 from the paternal chromosome and H19 from the maternal chromosome (red arrows). Middle panel — erasure of
imprinting at the Igf2-H19 locus as seen in primordial germ cells (PGCs) and pluripotent stem cells residing post-develop-
mentally in adult tissues (VSELs). DMRs on both the paternal and maternal chromosomes are engaged by the CTCF
insulator protein, and thus only H19 mRNA is transcribed (red arrows), contributing to the quiescent state of cells
(lacking autocrine IGF2). Lower panel — loss of imprinting at the Igf2-H19 locus as seen in tumor cells from several types
of cancer (e.g. rhabdomyosarcoma, nephroblastoma, and gastrointestinal tumors). Since both DMRs are methylated,
the insulator protein CTCF cannot bind to the DNA and the distal enhancer stimulates transcription of mRNA for IGF2
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utes to body size and muscle mass of the developing
fetus, and wants the mother to devote as much of her
resources as possible towards the growth of his off-
spring, the mother wants to conserve as much of her
resources as possible towards future births (without
compromising the health of the fetus she is carrying)
by epigenetic modulation of genes by maternal im-
printing marks (i.e. to achieve suppression of Igf2 and
expression of H19) [4].
It is well known that IGF2 is secreted from cells in
an autocrine or paracrine manner and exerts its bio-
logical effects after binding to the insulin-like growth
factor-1 (IGF1) receptor (IGF-1R). On the other
hand, IGF2 may also bind to non-signaling insulin-
-like growth factor-2 receptor (IGF-2R), which is
a mannose 6-phosphate receptor that acts as a decoy
receptor for IGF2 and prevents its signaling through
IGF-1R [17]. Overall, the IGF2 level is high in hu-
mans during embryogenesis and in postnatal life may
be produced and secreted by some tumors, causing
their proliferation and hypoglycemia as part of the
paraneoplastic syndrome. The loss of imprinting at
the Igf2-H19 locus (Figure 1, middle panel) leads to
overexpression of Igf2, which is observed in Beckwith–
–Wiedemann syndrome and is associated with orga-
nomegaly of newborns and a high incidence of sever-
al pediatric sarcomas (e.g. rhabdomyosarcoma and
nephroblastoma) [18, 19].
In contrast, H19, as mentioned above, is a long,
2.3-kb, non-coding RNA (ncRNA) transcribed from
the maternally inherited allele only; it is highly ex-
pressed prenatally and downregulated postnatally. It
is well known that H19 ncRNA, which is evolution-
arily conserved at the nucleotide level in humans and
rodents and not translated to protein, is processed
into small miRNAs [15]. This is supported by the find-
ing that in situ hybridization of the H19 ncRNA re-
vealed that it is detectable in cytoplasmic ribonucle-
oprotein particles, which suggests that H19-derived
miRNAs are involved in ribosomal function and trans-
lation. However, the loss of H19 is not lethal in mice,
http://en.wikipedia.org/wiki/H19_(gene) and such an-
imals display an overgrowth phenotype similar to ba-
bies with Beckwith–Wiedemann syndrome, while the
overexpression of H19 is a dominant lethal mutation;
mouse embryos overexpressing H19 die after embry-
onic day 14.
The close coupling of Igf2 and H19 expression is
explained by the fact that these two genes share the
same 3’ gene enhancer (Figure 1). It has been report-
ed that deletion of this 3’ enhancer results in down-
regulation of both Igf2 and H19 expression. Further-
more, there are some indications that the 3’ enhanc-
er has a more robust effect on the expression of H19
than Igf2. This could be explained by the facts that:
1) H19 has a stronger promoter than Igf2 [4, 14]; and
2) that the H19 gene is physically closer to the 3’ en-
hancer than Igf2 (Figures 1 and 2).
The expression of Igf2-H19 is regulated from the
3’ enhancer by the transcriptional zinc finger DNA-
-binding protein repressor, CTCF (also known as
CCCTC-DNA sequence binding factor). The human
genome contains nearly 15,000 CTCF insulator sites,
suggesting a widespread role of CTCF in gene regula-
tion [5, 14, 16]. What is of importance for this review is
that this DNA-binding regulatory protein is involved
in insulator activity for Igf2 expression by binding to
the DMR at the Igf2-H19 locus (Figure 1). Binding to
the methylation-free DMR by CTCF blocks the inter-
action between the 3’ distal enhancer and the promot-
er of Igf2, while not affecting H19 expression. Overall,
four CTCF binding sites have been identified in the
murine Igf2-H19 DMR and seven in the human coun-
terpart. Interestingly, the human Igf2-H19 DMR is not
able to function when introduced as a transgene into
the murine genome, which suggests differences in the
regulation of this DMR between species [14].
In conclusion, proper imprinting of the Igf2-H19
locus is required for the balanced expression of both
genes in somatic cells and in normal embryonic de-
velopment.
Biological consequences of erasure of
imprinting at the DMR for the Igf2-H19
tandem gene in primordial germ cells (PGCs)
The erasure of methylation in the DMR for Igf2-H19
(Figure 2, middle panel) leads to downregulation of
growth-promoting Igf2 from both paternal and ma-
ternal chromosomes and overexpression of prolifer-
ation-limiting H19. Therefore, cells that undergo such
epigenetic modification tend to remain in a quiescent
state, and this occurs early in the development of
PGCs [6–11]. Accordingly, PGCs, while they migrate
during embryogenesis through the embryo proper into
the genital ridges, erase several maternally and pa-
ternally imprinted loci, including the Igf2-H19 locus.
This mechanism of erasure of imprinted marks has
several important consequences. First, it prevents
these cells from uncontrolled proliferation and the
potential risk of teratoma formation. Second, it cre-
ates in mammals a barrier against parthenogenetic
development [4].
Furthermore, after the erasure of imprinting,
PGCs are not able to proliferate in vitro and do not
complement blastocyst development, while nuclei
harvested from PGCs are not capable of performing
as DNA donors in therapeutic cloning. However, all
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these limitations in the pluripotency of PGCs are re-
versed when their imprinting is re-established during
ex vivo generation from PGCs of embryonic germ cells
(EGCs) [6–11].
During normal development, proper imprinting in
germ line cells is established in later stages when
PGCs, after colonization of the genital ridges, devel-
op into gametes — oocytes or sperm. Proper imprint-
ing is established in female germ line (paternal im-
printing) and male germ line (maternal imprinting)
cells after a first meiotic division when the chromo-
somes are reduced to haploid number. Thus, when
haploid gametes fuse during fertilization, the chro-
mosomes in the diploid zygote have proper imprint-
ing, including at the Igf2-H19 loci.
As mentioned above, the importance of proper
imprinting of Igf2-H19 during embryogenesis has also
been demonstrated during generation of viable bima-
ternal mice [20]. The bimaternal zygote is generated
from two female sets of chromosomes without par-
ticipation of a paternal genome by combining two
haploid nuclei from non-growing oocytes — one de-
rived from a newborn pup and another from a fully
grown oocyte. Since female chromosomes have unm-
ethylated DMRs for Igf2-H19, the proper expression
of Igf2 and H19 in this mouse was achieved by appro-
priate genetic modification of the Igf2-H19 locus on
one set of female chromosomes to ensure that this
locus expresses Igf2 [20].
Biological consequences of erasure of
imprinting in the DMR of the Igf2-H19
tandem gene in very small embryonic-like
stem cells (VSELs)
Modification of genomic imprinting also plays a cru-
cial role in maintaining the pool of pluripotent stem
cells residing in adult tissues. Recently, our group
demonstrated that adult murine tissues harbor a pop-
ulation of pluripotent Oct4+ SSEA-1+Sca-1+Lin–
CD45– cells [21, 22]. We have also identified a corre-
sponding population of cells that are Oct-4+SSEA-
4+CD133+Lin–CD45– in humans as well [23, 24]. We
hypothesize that these PSCs, which are called VSELs,
are deposited in adult tissues, including during early
embryogenesis, and serve as a backup for tissue-com-
mitted stem cells (TCSCs). Molecular analysis of
VSELs has revealed that their quiescence in adult BM
and premature depletion from the tissues is controlled
by epigenetic changes to imprinted genes, including
the Igf2-H19 locus, which is erased in murine VSELs
[12, 13] (Figure 2, middle panel).
Murine VSELs, in addition to erasure at the
Igf2-H19 locus, also modify expression of other
imprinted genes. For example, we observed that mu-
rine BM-sorted VSELs erase the paternally methylat-
ed imprints (e.g. DMRs at the Igf2-H19 and RasGrf1
loci, Figure 3), while they hypermethylate the mater-
nally methylated imprints (e.g. DMRs at Igf2R). The
epigenetic modification of imprinted loci (including
Igf2-H19) prevents VSELs from uncontrolled prolif-
eration and, as in the case of PGCs, prevents them
from teratoma formation. The epigenetic modifica-
tion of imprinted genes also explains why VSELs,
despite expressing several markers of pluripotency
(e.g. open chromatin structure at the promoters for
Oct-4 and Nanog), the presence of bivalent domains
at developmentally important homeobox-domain con-
taining genes, the reactivation of the X chromosome
in female VSELs, and in vitro differentiation into cells
from all three germ layers, do not complement blas-
tocyst development after injection into the pre-im-
plantation blastocyst [12, 13].
There are also other important implications for
erasure of paternally imprinted genes in VSELs.
Namely, the erasure at the paternally imprinted
Igf2-H19 and RasGrf1 loci leads to impair insulin/in-
sulin-like growth factor signaling (IIS) in these cells
[25–27]. This has a potential impact on the role of
VSELs in tissue rejuvenation and aging as well as on
the involvement of these cells in tumorogenesis.
Erasure of imprinting at the Igf2-H19 locus in
VSELs and its implications for
tissue rejuvenataion and aging
The abovementioned changes in expression of im-
printed genes in VSELs lead to perturbation of IIS
by downregulation of IGF2, which is an autocrine
factor involved in proliferation of VSELs, and down-
regulation of RasGRF1, which is a GTP-exchange
factor (GEF) crucial for signaling from IGF-IR and
the insulin receptor (InsR, Figure 3). In addition, in
VSELs we observed hypermethylation of DMRs on
the maternal chromosome encoding IGF-2R [12, 13],
which, as mentioned above, serves as a decoy recep-
tor that prevents IGF-2 from binding to IGF-IR [25].
Overall, this epigenetic reprogramming of genomic
imprinting negatively affects IIS signaling, maintains
the quiescent state of VSELs and thus protects them
from premature depletion from the tissues, and pre-
vents their involvement in tumor formation.
Based on these findings, we propose a novel hypoth-
esis that relates aging, longevity, and IIS to the abun-
dance and function of pluripotent VSELs deposited in
adult tissues. A decrease in the number of these cells
should negatively affect pools of TCSCs in various or-
gans and have an impact on tissue rejuvenation and
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lifespan [25–28]. In support of this expectation, we ob-
served a significantly higher number of VSELs in long-
-living murine strains (e.g. Laron dwarfs and Ames
dwarfs) whose longevity is explained by low levels of cir-
culating IGF1 [29–32]. In contrast, the number of VSELs
is reduced compared to normally aging littermates in
mice with high levels of circulating IGF1 (e.g. growth
hormone-overexpressing transgenic mice) [32].
Attempting to summarize all of this, the influence
of IIS on the pool of VSELs residing in adult tissues
seems to be twofold (Figure 4). In the first scenario,
IGF2 is an autocrine factor for these cells, explaining
why both downregulation of expression of Igf2 and
RasGrf1 together with elevated expression of H19 and
upregulation of IGF-2R, which is a decoy receptor for
IGF2, keeps these cells quiescent. However, we ob-
served that with increasing age, the methylation pat-
tern of DMRs at paternally imprinted genes in VSELs
reverses and Igf2-H19, as well as RasGrf1 loci, become
gradually methylated, and thus VSELs become more
sensitive to IIS [26–28]. This phenomenon may con-
tribute to their age-related depletion over time.
On the other hand (second scenario), VSELs ex-
press functional IGF-1R and InsR and are suscepti-
ble to exogenous circulating IGF1 and insulin (Ins).
Therefore, a chronic increase in caloric uptake that
elevates circulating levels of these hormones may con-
tribute over time to the depletion of these cells from
adult tissues, affect the generation of VSEL-derived
TCSCs, and thus negatively affect lifespan. In sup-
port of this scenario, we demonstrated that mice that
have high levels of circulating blood plasma IGF1
show accelerated depletion of VSELs and have
a shorter lifespan than age-matched littermates.
Erasure of imprinting at the Igf2-H19 locus in
VSELs and its potential role in cancerogenesis
The changes in imprinting of the Igf2-H19 locus may
be involved in tumor formation. A growing body of
evidence suggests that cancer originates in the stem/
/progenitor cell compartment. This stem-cell-origin-
-of-cancer hypothesis is based on the assumption that
self-renewing stem cells residing in organs and tis-
sues, and not mature differentiated somatic cells such
as those lining the bronchial or stomach mucosa, may
accumulate mutations over a lifetime [33, 34]. These
mutations are subsequently maintained in stem cell
compartments, and self-renewing stem cells may be
subjected to additional mutations and epigenetic
changes so that the genome is destabilized and un-
controlled neoplastic proliferation is initiated.
Interestingly, during the 19th and early 20th centu-
ries, several investigators proposed that cancer de-
Figure 3. Erasure of genomic imprinting for paternally methylated imprinted genes in murine VSELs, HSCs, MSCs, and
the ES-D3 cell line. Bisulfite sequencing profiles of DNA methylation of DMRs for Igf2-H19 (upper panel) and RasGrf1
(lower panel) loci in VSELs, hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and the murine embry-
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velops in populations of cells that are left in a dor-
mant state in developing organs during embryogene-
sis [34]. This ‘embryonic rest’ hypothesis of cancer
origin suggested that adult tissues contain embryonic
remnants that normally lie dormant, but can be acti-
vated to become cancerous. Based on the presence
of VSELs in adult tissues, we hypothesize that VSELs
could be the missing link that reconciles the embry-
onic rest hypothesis of cancer origin with current the-
ories envisioning cancer as a stem cell disorder.
In support of this perspective, it is well known that
obesity and high caloric uptake are risk factors for
cancer development. Experimental animals with high
levels of circulating IGF1 are not only short-lived but
also have a high incidence of cancer [35]. On the oth-
er hand, long-living animals with low levels of circu-
lating IGF2 have a much lower incidence of tumor
growth [32]. This correlates with human Laron dwarfs
that have a very low level of circulating IGF1 and at
the same time are prone to cancer development [29,
32]. Based on these observations, we envision that
chronic stimulation of VSELs by IIS may activate
these cells in an uncontrolled way and promote their
malignant growth. Therefore, it is likely that some
human tumors originate in VSELs, and that IIS may
play an important initiating role. Again, we envision
here two possible mechanisms. Firstly VSELs exposed
to a constant high circulating IGF1 level could trans-
form into neoplastic cells; and secondly, as discussed
below, they could transform due to a loss of imprint-
ing at the Igf2-H19 locus that will expose them to au-
tocrine IGF2.
Consequences for tumorogenisis of the loss
of imprinting at the DMR for the Igf2-H19
tandem gene
There is growing evidence that the autocrine IGF2–
–IGF-1R loop, due to loss of imprinting at the
Igf2-H19 locus (Figure 2, lower panel), may be involved
Figure 4. Two scenarios for how insulin/insulin-like growth factor signaling (IIS) may affect the pool of VSELs. VSELs are
deposited in adult tissues as a backup population for tissue committed stem cells. Left panel — increase in autocrine-
-secreted IGF2, due to gradual loss of imprinting at the Igf2-H19 locus as observed during aging, stimulates VSELs via
IGF-1R. This leads to an age-mediated VSEL depletion, and as a consequence a decrease in VSEL-generated tissue-
-committed stem cells (TCSCs), and impairs tissue organ rejuvenation. Right panel — VSELs deposited in adult tissues
may, over time, become depleted more quickly by chronic elevated circulating levels of IGF1 and insulin that engage
IGF1R and InsR expressed by these cells. This may contribute to accelerated aging observed in situations with high
circulating IGF1 and insulin level (e.g. high calorie uptake). On other hand, this mechanism of chronic exposure to IIS
may also lead to malignant transformation of VSELs after prolonged stimulation by IGF1 and insulin. For the sake of
simplicity, two other proteins encoded by imprinted genes that affect IIS are not shown — paternally imprinted RasGrf1,
which due to erasure of imprinting is not expressed in VSELs, and maternally imprinted IGF-2R, which due to hyperme-
thylation of the DMR locus on the maternal chromosome, is highly expressed in these cells. While RasGRF1 is an
important component of IIS from activated IGF-1R and InsR, IGF-2R serves as a decoy receptor for IGF2. Therefore,
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in the growth of several types of tumors. The best ex-
ample, as mentioned above, is Beckwith–Wiedemann
syndrome, which is associated with the development
of several pediatric sarcomas. The loss of imprinting
at the Igf2-H19 locus is a very well-known phenome-
non observed both in Beckwith–Wiedemann syn-
drome-related and spontaneous human rhabdomyo-
sarcomas and nephroblastomas. Loss of imprinting
at this locus has also been described in gastrointesti-
nal tumors, both in humans and in mice [36–39].
Furthermore, as mentioned above, one of the fea-
tures of aging VSELs is gradual hypermethylation of
DMRs for Igf2-H19 locus on the maternal chromo-
some that due to this ‘age-related’ loss of imprint leads
to overexpression of IGF2 [26–28]. This may corre-
spond to a higher incidence of cancer in advanced
age. The deregulation of the Igf2-H19 locus observed
in several tumors raises the question of the cell of
origin in which this genetic defect originates. As dis-
cussed above, one possibility is that this event occurs
in VSELs [33, 34]. This hypothesis, however, requires
further studies.
Conclusions
Evidence has accumulated that the imprinted Igf2-
H19 tandem gene plays a pleiotropic role in several
biological processes. Expression of this locus is tight-
ly regulated by genomic imprinting and the CTCF
protein, which is involved in the balanced expression
of both genes from either paternal or maternal chro-
mosomes. In addition, an interesting mechanism has
been described in which elevated levels of IGF2 in
senescent human epithelial cells are the result of
a reduction in CTCF expression, which controls the
Igf2-H19 locus. As reported, an increase in the intra-
cellular CTCF level, leading to lower occupancy
of DMRs by CTCF within Igf-H19 loci, resulted in
a 10-fold increase in intracellular Igf2 expression [14].
Furthermore, it is likely that, in addition to CTCF,
other proteins are also involved in the regulation of
this locus and that they still await identification. Mod-
ification of expression at the Igf2-H19 locus may have
an important role in inhibiting aging processes and pre-
venting cancerogenesis. Furthermore, as we envision,
proper methylation of the DMR at this locus, which is
erased in VSELs [12, 13], will be crucial for the devel-
opment of ex vivo strategies for the expansion of VSELs
for the purposes of regenerative medicine [40].
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